Bristol-Myers Squibb Co. (BMY) Financials
Key financial figures for Bristol-Myers Squibb Co. (Q2 2026).
Bristol Myers Squibb raised full-year 2026 revenue guidance to $49.0-$50.0 billion after Q2 revenue grew 6% to $13.0 billion, powered by 15% Growth Portfolio growth. Q2 2026 total revenues of $13.0 billion, up 6% (+5% ex-FX) year-over-year, ahead of the prior quarter's pace GAAP EPS of $1.62 and non-GAAP EPS of $2.04, both up sharply from $0.64 and $1.46 a year ago Growth Portfolio revenue rose 15% to $7.6 billion, led by Opdivo Qvantig (>200%), Camzyos (+45%), Breyanzi (+39%) and Opdualag (+17%) Legacy Portfolio revenue fell 4% to $5.4 billion as Eliquis demand (+27% domestically) partly offset accelerating Revlimid generic erosion (-52%) Gross margin contracted 120bps to 71.3% GAAP on product mix shift Management raised full-year revenue guidance to ~$49. On the outlook: Raised FY2026 revenue guidance to approximately $49.0-$50.0 billion (from $46.0-$47.5 billion) and non-GAAP EPS guidance to $6.75-$7.00 (from $6.05-$6.35). Figures are for Q2 2026, as Bristol Myers Squibb Company reported them.
- Revenue
- $13.0B
- Net Income
- $3.3B
- EPS
- $1.62
- Total Assets
- $87.6B
- Operating Cash Flow
- $3.4B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $13.0B | $3.3B | $1.62 | 31.5% | $3.1B |
| Q1 FY2026 | $11.5B | $2.7B | $1.31 | 29.29% | $757M |
| Q4 FY2025 | $12.5B | $1.1B | $0.53 | 22.5% | $1.6B |
| Q3 FY2025 | $12.2B | $2.2B | $1.08 | 29.77% | $6.0B |
| Q2 FY2025 | $12.3B | $1.3B | $0.64 | 30.76% | $3.6B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $48.2B | $7.1B | $3.45 | 28.48% | $12.8B |
| FY2024 | $48.3B | -$8.9B | -$4.41 | 20% | $13.9B |
| FY2023 | $45.0B | $8.0B | $3.86 | 18.82% | $12.7B |
Frequently asked questions
What was Bristol Myers Squibb Company's revenue last quarter?
Bristol Myers Squibb Company reported revenue of $12.97 billion for Q2 FY2026, up 5.7% from the same period a year earlier.
Is Bristol Myers Squibb Company profitable?
Yes. Bristol Myers Squibb Company reported net income of $3.32 billion for Q2 FY2026, a net margin of 25.57% on revenue.
How has Bristol Myers Squibb Company's margin trended?
Operating margin was 31.5% in Q2 FY2026, compared with 30.76% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Bristol Myers Squibb Company generate?
Bristol Myers Squibb Company generated free cash flow of $3.09 billion in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Bristol-Myers Squibb Co. on SentiSense, with up to forty quarters and twenty fiscal years of history.